Last reviewed · How we verify
HWK-016, MUCIN-16-targeted ADC
HWK-016, MUCIN-16-targeted ADC is a Small molecule drug developed by Whitehawk Therapeutics, Inc.. It is currently in Phase 1 development. Also known as: HWK-016.
At a glance
| Generic name | HWK-016, MUCIN-16-targeted ADC |
|---|---|
| Also known as | HWK-016 |
| Sponsor | Whitehawk Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HWK-016, MUCIN-16-targeted ADC CI brief — competitive landscape report
- HWK-016, MUCIN-16-targeted ADC updates RSS · CI watch RSS
- Whitehawk Therapeutics, Inc. portfolio CI
Frequently asked questions about HWK-016, MUCIN-16-targeted ADC
What is HWK-016, MUCIN-16-targeted ADC?
HWK-016, MUCIN-16-targeted ADC is a Small molecule drug developed by Whitehawk Therapeutics, Inc..
Who makes HWK-016, MUCIN-16-targeted ADC?
HWK-016, MUCIN-16-targeted ADC is developed by Whitehawk Therapeutics, Inc. (see full Whitehawk Therapeutics, Inc. pipeline at /company/whitehawk-therapeutics-inc).
Is HWK-016, MUCIN-16-targeted ADC also known as anything else?
HWK-016, MUCIN-16-targeted ADC is also known as HWK-016.
What development phase is HWK-016, MUCIN-16-targeted ADC in?
HWK-016, MUCIN-16-targeted ADC is in Phase 1.
Related
- Manufacturer: Whitehawk Therapeutics, Inc. — full pipeline
- Also known as: HWK-016
- Compare: HWK-016, MUCIN-16-targeted ADC vs similar drugs
- Pricing: HWK-016, MUCIN-16-targeted ADC cost, discount & access